Silverfin false false 28/02/2026 01/03/2025 28/02/2026 A Youds 07/02/2020 05 August 2026 no description of principal activity 12450559 2026-02-28 12450559 bus:Director1 2026-02-28 12450559 2025-02-28 12450559 core:CurrentFinancialInstruments 2026-02-28 12450559 core:CurrentFinancialInstruments 2025-02-28 12450559 core:ShareCapital 2026-02-28 12450559 core:ShareCapital 2025-02-28 12450559 core:RetainedEarningsAccumulatedLosses 2026-02-28 12450559 core:RetainedEarningsAccumulatedLosses 2025-02-28 12450559 core:FurnitureFittings 2025-02-28 12450559 core:ComputerEquipment 2025-02-28 12450559 core:FurnitureFittings 2026-02-28 12450559 core:ComputerEquipment 2026-02-28 12450559 core:WithinOneYear 2026-02-28 12450559 core:WithinOneYear 2025-02-28 12450559 core:BetweenOneFiveYears 2026-02-28 12450559 core:BetweenOneFiveYears 2025-02-28 12450559 2025-03-01 2026-02-28 12450559 bus:FilletedAccounts 2025-03-01 2026-02-28 12450559 bus:SmallEntities 2025-03-01 2026-02-28 12450559 bus:AuditExemptWithAccountantsReport 2025-03-01 2026-02-28 12450559 bus:PrivateLimitedCompanyLtd 2025-03-01 2026-02-28 12450559 bus:Director1 2025-03-01 2026-02-28 12450559 core:FurnitureFittings 2025-03-01 2026-02-28 12450559 core:ComputerEquipment 2025-03-01 2026-02-28 12450559 2024-03-01 2025-02-28 iso4217:GBP xbrli:pure

Company No: 12450559 (England and Wales)

# PHARMECONOMY LTD

### UNAUDITED FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 28 FEBRUARY 2026
PAGES FOR FILING WITH THE REGISTRAR

PHARMECONOMY LTD

## UNAUDITED FINANCIAL STATEMENTS

FOR THE FINANCIAL YEAR ENDED 28 FEBRUARY 2026

Contents

PHARMECONOMY LTD

## COMPANY INFORMATION

FOR THE FINANCIAL YEAR ENDED 28 FEBRUARY 2026
PHARMECONOMY LTD

## COMPANY INFORMATION (continued)

FOR THE FINANCIAL YEAR ENDED 28 FEBRUARY 2026

DIRECTOR | A Youds

REGISTERED OFFICE | Wey Court West
| Union Road
| Farnham
| Surrey
| GU9 7PT
| United Kingdom

COMPANY NUMBER | 12450559 (England and Wales)

ACCOUNTANT | Shaw Gibbs Limited
| Wey Court West
| Union Road
| Farnham
| Surrey
| GU9 7PT

PHARMECONOMY LTD

## STATEMENT OF FINANCIAL POSITION

AS AT 28 FEBRUARY 2026
PHARMECONOMY LTD

## STATEMENT OF FINANCIAL POSITION (continued)

AS AT 28 FEBRUARY 2026

| Note | 2026 |  | 2025
|  | £ |  | £
Fixed assets |  |  |  |
Tangible assets | 3 | 4,187 |  | 4,137
|  | 4,187 |  | 4,137
Current assets |  |  |  |
Debtors | 4 | 4,886 |  | 8,675
Cash at bank and in hand |  | 7,065 |  | 18,786
|  | 11,951 |  | 27,461
Creditors: amounts falling due within one year | 5 | ( 12,832) |  | ( 30,539)
Net current liabilities |  | (881) |  | (3,078)
Total assets less current liabilities |  | 3,306 |  | 1,059
Provision for liabilities |  | ( 1,047) |  | ( 852)
Net assets |  | 2,259 |  | 207
Capital and reserves |  |  |  |
Called-up share capital |  | 1 |  | 1
Profit and loss account |  | 2,258 |  | 206
Total shareholder's funds |  | 2,259 |  | 207

For the financial year ending 28 February 2026 the Company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

- The member has not required the Company to obtain an audit of its financial statements for the financial year in accordance with section 476;
- The director acknowledges their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements; and
- These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime and a copy of the Statement of Income and Retained Earnings has not been delivered.

The financial statements of PharmEconomy Ltd (registered number: 12450559) were approved and authorised for issue by the Director on 05 August 2026. They were signed on its behalf by:

A Youds Director |

PHARMECONOMY LTD

## NOTES TO THE FINANCIAL STATEMENTS

FOR THE FINANCIAL YEAR ENDED 28 FEBRUARY 2026
PHARMECONOMY LTD

## NOTES TO THE FINANCIAL STATEMENTS

FOR THE FINANCIAL YEAR ENDED 28 FEBRUARY 2026

##### 1. Accounting policies

The principal accounting policies are summarised below. They have all been applied consistently throughout the financial year and to the preceding financial year, unless otherwise stated.

##### General information and basis of accounting

PharmEconomy Ltd (the Company) is a private company, limited by shares, incorporated in the United Kingdom under the Companies Act 2006 and is registered in England and Wales. The address of the Company's registered office is Wey Court West, Union Road, Farnham, Surrey, GU9 7PT , United Kingdom.
The financial statements have been prepared under the historical cost convention, modified to include certain items at fair value, and in accordance with Section 1A of Financial Reporting Standard 102 (FRS 102) ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland’ issued by the Financial Reporting Council and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.
The financial statements are presented in pounds sterling which is the functional currency of the Company and rounded to the nearest £.

##### Turnover

Turnover is stated net of VAT and trade discounts and is recognised when the significant risks and rewards are considered to have been transferred to the buyer. Turnover from the supply of services represents the value of services provided under contracts to the extent that there is a right to consideration and is recorded at the fair value of the consideration received or receivable. Where a contract has only been partially completed at the Statement of Financial Position date turnover represents the fair value of the service provided to date based on the stage of completion of the contract activity at the Statement of Financial Position date. Where payments are received from customers in advance of services provided, the amounts are recorded as deferred income and included as part of creditors due within one year.

##### Interest income

Interest income is recognised when it is probable that the economic benefits will flow to the Company and the amount of revenue can be measured reliably. Interest income is accrued on a time basis, by reference to the principal outstanding at the effective interest rate applicable, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to that asset's net carrying amount on initial recognition.

##### Taxation

Current tax
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement except to the extent that it relates to items recognised in other comprehensive income or directly in equity.
Current or deferred taxation assets and liabilities are not discounted.
Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.
Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.
Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.
Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

##### Tangible fixed assets

Tangible fixed assets are stated at cost or valuation, net of depreciation and any provision for impairment. Depreciation is provided on all tangible fixed assets, other than investment property and freehold land, at rates calculated to write off the cost or valuation, less estimated residual value, of each asset on a straight-line or reducing balance basis over its expected useful life, as follows:

Fixtures and fittings | 25 % reducing balance
Computer equipment | 25 % reducing balance

Depreciation methods, useful lives and residual values are reviewed at each balance sheet date. The selection of these residual values and estimated lives requires the exercise of judgement. The directors are required to assess whether there is an indication of impairment to the carrying value of assets. In making that assessment, judgements are made in estimating value in use. The directors consider that the individual carrying values of assets are supportable by their value in use.
The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

##### Leases

The Company as lessee
Assets held under finance leases, hire purchase contracts and other similar arrangements, which confer rights and obligations similar to those attached to owned assets, are capitalised as tangible fixed assets at the fair value of the leased asset (or, if lower, the present value of the minimum lease payments as determined at the inception of the lease) and are depreciated over the shorter of the lease terms and their useful lives. The capital elements of future lease obligations are recorded as liabilities, while the interest elements are charged to the Statement of Income and Retained Earnings over the period of the leases to produce a constant periodic rate of interest on the remaining balance of the liability.
Rentals under operating leases are charged on a straight-line basis over the lease term, even if the payments are not made on such a basis. Benefits received and receivable as an incentive to sign an operating lease are similarly spread on a straight-line basis over the lease term.

##### Trade and other debtors

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts, except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

##### Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in creditors: amounts falling due within one year.

##### Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

##### Financial instruments

Financial assets and financial liabilities are recognised when the Company becomes a party to the contractual provisions of the instrument.
Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the Company after deducting all of its liabilities.
Financial assets and liabilities are only offset in the Balance Sheet when, and only when there exists a legally enforceable right to set off the recognised amounts and the Company intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

##### Provisions

Provisions are recognised when the Company has a present obligation (legal or constructive) as a result of a past event, it is probable that the Company will be required to settle that obligation and a reliable estimate can be made of the amount of the obligation.
The amount recognised as a provision is the best estimate of the consideration required to settle the present obligation at the Statement of Financial Position date, taking into account the risks and uncertainties surrounding the obligation. Where a provision is measured using the cash flows estimated to settle the present obligation, its carrying amount is the present value of those cash flows (when the effect of the time value of money is material).

##### Dividends

Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting.

#### 2. Employees

| 2026 |  | 2025
| Number |  | Number
Monthly average number of persons employed by the Company during the year, including the director | 1 |  | 1

#### 3. Tangible assets

| Fixtures and fittings |  | Computer equipment |  | Total
| £ |  | £ |  | £
Cost |  |  |  |  |
At 01 March 2025 | 5,018 |  | 6,114 |  | 11,132
Additions | 0 |  | 1,157 |  | 1,157
Disposals | 0 |  | ( 1,120) |  | ( 1,120)
At 28 February 2026 | 5,018 |  | 6,151 |  | 11,169
Accumulated depreciation |  |  |  |  |
At 01 March 2025 | 3,259 |  | 3,736 |  | 6,995
Charge for the financial year | 440 |  | 667 |  | 1,107
Disposals | 0 |  | ( 1,120) |  | ( 1,120)
At 28 February 2026 | 3,699 |  | 3,283 |  | 6,982
Net book value |  |  |  |  |
At 28 February 2026 | 1,319 |  | 2,868 |  | 4,187
At 28 February 2025 | 1,759 |  | 2,378 |  | 4,137

#### 4. Debtors

| 2026 |  | 2025
| £ |  | £
Trade debtors | 3,600 |  | 4,140
Prepayments | 1,286 |  | 2,241
Other debtors | 0 |  | 2,294
| 4,886 |  | 8,675

#### 5. Creditors: amounts falling due within one year

| 2026 |  | 2025
| £ |  | £
Accruals | 1,850 |  | 1,700
Taxation and social security | 10,918 |  | 28,839
Other creditors | 64 |  | 0
| 12,832 |  | 30,539

#### 6. Financial commitments

Commitments

Total future minimum lease payments under non-cancellable operating leases are as follows:

| 2026 |  | 2025
| £ |  | £
within one year | 7,714 |  | 10,284
between one and five years | 0 |  | 7,714
Total future minimum lease payments under non-cancellable operating leases | 7,714 |  | 17,998